Revisiting the ultimate target of treatment for prostate cancer
- PMID: 20398924
- DOI: 10.1016/S0140-6736(10)60400-X
Revisiting the ultimate target of treatment for prostate cancer
Comment on
-
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.Lancet. 2010 Apr 24;375(9724):1437-46. doi: 10.1016/S0140-6736(10)60172-9. Epub 2010 Apr 14. Lancet. 2010. PMID: 20398925 Free PMC article. Clinical Trial.
Similar articles
-
Enzalutamide (Xtandi) for prostate cancer.Med Lett Drugs Ther. 2013 Mar 4;55(1411):e20. Med Lett Drugs Ther. 2013. PMID: 23467121 No abstract available.
-
[2017 ASCO: Complete androgen blockade strikes back].Bull Cancer. 2017 Jul-Aug;104(7-8):599-601. doi: 10.1016/j.bulcan.2017.06.001. Epub 2017 Jul 5. Bull Cancer. 2017. PMID: 28688745 French. No abstract available.
-
[The molecular mechanisms of resistance to androgen deprivation therapy in prostate cancer].Nihon Rinsho. 2012 Nov;70 Suppl 8:353-9. Nihon Rinsho. 2012. PMID: 23513865 Japanese. No abstract available.
-
The role of enzalutamide in the treatment of castration-resistant prostate cancer.Future Oncol. 2012 Sep;8(9):1073-81. doi: 10.2217/fon.12.99. Future Oncol. 2012. PMID: 23030482 Review.
-
Beyond castration and chemotherapy: novel approaches to targeting androgen-driven pathways.Maturitas. 2009 Oct 20;64(2):61-6. doi: 10.1016/j.maturitas.2009.08.004. Epub 2009 Sep 5. Maturitas. 2009. PMID: 19733987 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical